RE: Article19 Apr 2020 15:20
I'm not too sure the article should be taken too literally.
They say - "Tracking last 52 weeks, the stock 52 week high price observed at GBX19 +0.00% and 52 week low seen at GBX7 -63.16%. "
So they are talking 19p as the current price at time of writing.
Then they say - "Analysts also expected that stock to achieve share value at GBX1,611 +8,377.72% in coming one year period"
So that isn't 161p it is 1611p ie £16.11. Current market cap is around £120M - so 1611p gives a value of around £9Bn.
I'd say that was a tad optimistic.
YGEN also issued guidance on 8th April last year but none this year, thus far. I suspect that they might have been intending to issue guidance but COVID19 has turned everything upside down. There are hints that they are very busy, but presumably the NCYT and NHS contracts will involve some additional costs being incurred initially prior to invoicing and payment taking place.
The year up to March 2020 will be effectively irrelevant as regards forwards guidance, and as yet they don't know what the actual revenues for 2020 will be, apart from the fact that they are likely to be be significantly ahead at this early stage. Hence no April update as yet.
Hopefully we will get some indications shortly on what exactly the COVID work means to YGEN, but even NCYT appear reluctant to put financial numbers to the COVID work that they are doing probably because they at present don't know the magnitude of what it means P&L wise medium term.
No doubt the numbers will come in time and lead to a significant re rate for both - but maybe 1611p for YGEN is going it a bit.